Why choose Liquid Select?

Historically, the majority of assays for clinically meaningful molecular alterations have relied on a tissue sample from the
tumor. However, obtaining tissue samples for lung cancer patients can be challenging. From a simple blood draw, Liquid
Select detects specific genomic alterations that can help you quickly evaluate treatment options, by focusing on genes
identified in the National Comprehensive Cancer Network (NCCN®) guideline as relevant to FDA-approved therapies
and relevant Phase II-IV clinical trials that are currently enrolling.

Liquid Select may be a good choice when:

The patient is hard to biopsy or when the risk of biopsy may outweigh the benefit.

Tumor tissue is not readily available, or is “quantity not sufficient” (QNS).

Tumor tissue has been submitted for mutation testing, but the tissue test failed.

Heterogeneity of the tumor may be important.

Your patient is undergoing treatment but is progressing on therapy.

A tissue surrogate is needed at disease progression, to determine evolution of tumor or for newly recurrent patients for whom testing of archival diagnostic tissue may not be relevant.

You want to identify alternate actionable drivers to guide non-standard of care treatments.

Unlike large blood panels used for research studies, Liquid Select is focused and designed to be immediately actionable—connecting each patient to the treatments of greatest relevance to the precise molecular biology of their tumor. Other liquid biopsy tests typically use much larger gene panels that blend “clinically actionable” and “non-clinically actionable” genes—leading to lengthy reports that highlight alterations not necessarily associated with treatment options or eligibility for clinical trials.

Liquid Select includes select genomic cancer markers that have been:

Included in National Comprehensive Cancer Network (NCCN) guidelines*,

Associated with sensitivity or resistance to relevant FDA-approved therapies, or

Established as eligibility criteria for currently enrolling Phase II-IV clinical trials.

The concise, easy-to-interpret Liquid Select test report:

Indicates whether any clinically actionable variants are present in the patient’s blood sample.